ERBB2 and small cell lung carcinoma: We observed that SCLC mice treated with an ERBB2 and anti-PD-1 inhibitor displayed a higher number of circulating effective T cells, in comparison to vehicle-treated SCLC mice and healthy control mice (Fig. 8a).